Advertisement

Topics

FDA Announces New Review Process for Orphan Drug Designation

08:40 EDT 29 Jun 2017 | eCliniqua

Clinical Informatics News  Today, the U.S. Food and Drug Administration unveiled a strategic plan to eliminate the agency’s existing orphan designation request backlog and ensure continued timely response to all new requests for designation with firm deadlines.


 
 
 
 

Original Article: FDA Announces New Review Process for Orphan Drug Designation

NEXT ARTICLE

More From BioPortfolio on "FDA Announces New Review Process for Orphan Drug Designation"

Advertisement
Quick Search
Advertisement
Advertisement